Channel Partnerships Proven co-sell channels with Becton Dickinson and the Cardamom Health alliance demonstrate a scalable path to hospital contracts. Leverage BD's distribution footprint and Cardamom's multi-hospital network to drive adoption of Steripath for sepsis testing, bloodstream infection care, and antimicrobial stewardship programs.

Sales Momentum Leadership-driven growth signal: recent CEO appointment and a new Senior Vice President of Sales indicate intensified go-to-market execution and pipeline acceleration in enterprise hospital accounts.

Clinical Value Steripath reduces contamination leading to misdiagnosis of bloodstream infections and false-positive CLABSIs, supporting antimicrobial stewardship, improved patient outcomes, and hospital cost containment—strong buying rationale for infection prevention leaders and hospital procurement.

Differentiation Steripath Gen2 with integrated syringe and a large IP portfolio differentiate Magnolia from rivals, enabling potential licensing deals or co-development, and complementing BD's existing portfolio for faster adoption.

Growth Capacity With established funding and mid-market revenue, Magnolia has resources to scale field sales, expand within existing hospital networks, and pursue larger system-level deployments through its partnerships with BD and Cardamom Health.